Related Experiment Video

Updated: Aug 19, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative

Alexander Thiem1, Pegah Mashhadiakbar1, Christiane Cussigh2

  • 1Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.

Journal of the European Academy of Dermatology and Venereology : JEADV
|November 26, 2022
PubMed
Abstract

Insights

Systemic melanoma treatments impact daily life. Immune checkpoint inhibition (ICI) may offer better quality of life and fewer adverse events (AEs) than targeted therapy (TT), especially in the adjuvant setting.

Area of Science:

  • Oncology
  • Dermatology
  • Clinical Research

Background:

  • Systemic treatment selection for melanoma balances clinical factors and patient preferences.
  • Understanding treatment impact on patients' daily lives is crucial.

Purpose of the Study:

  • To evaluate how systemic therapy for melanoma affects patients' daily lives.
  • To compare patient-reported outcomes (PROs) between different systemic treatments.

Main Methods:

  • A cross-sectional study involving 414 melanoma patients across 13 German centers.
  • Utilized questionnaires to assess quality of life (QOL), adverse events (AEs), and treatment satisfaction.
  • Compared immune checkpoint inhibition (ICI) and targeted therapy (TT) groups.

Main Results:

  • Immune checkpoint inhibition (ICI) and targeted therapy (TT) were used in 87% and 13% of patients, respectively.
  • In the adjuvant setting, TT was associated with significantly lower QOL and higher AEs compared to ICI (p=0.02 and p=0.01).
  • Older patients (>63 years) reported better PROs and higher treatment satisfaction.

Conclusions:

  • Melanoma patients generally view their systemic treatments positively.
  • Immune checkpoint inhibition (ICI) may be preferable to targeted therapy (TT) for QOL and AEs in the adjuvant setting.
  • Older patients experience less disease/treatment burden and higher satisfaction.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
630
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K